Warren, R., Conrad, C., Foley, P., Iversen, L., Langley, R., Kokolakis, G., Davis, L., Vanvoorden, V., Wiegratz, S., & Merola, J. (2022). Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. SKIN The Journal of Cutaneous Medicine, 6(6), s70. https://doi.org/10.25251/skin.6.supp.70